A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma

Protocol No
TENEOBIO-TNB-383B
Principal Investigator
Anita D'Souza
Phase
I
Summary
TNB-383B is a type of drug known as an immunotherapeutic drug. Immunotherapy is a form of cancer treatment that uses the immune system to attack cancer cells, similar to the way it attacks bacteria or viruses. This type of therapy works by activating immune cells circulating in your body. Simply put, immunotherapy is a tool to trigger your body to treat the cancer itself. TNB-383B has been developed in a laboratory to make powerful 'killer' T-cells from your own immune system attack multiple myeloma cells in your body. TNB-383B is a bispecific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells, providing a signal that helps them grow. The second is called CD3 and is present on your killer T-cells. When CD3 is engaged on a T cell, it turns the T-cell on and makes it kill whatever cell triggered the activation. Because TNB-383B sticks very strongly to your myeloma cells, nearby T-cells should specifically attack your tumor cells.
Description
A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: